The stock of Ardelyx Inc (NASDAQ:ARDX) is a huge mover today! About 152,983 shares traded hands. Ardelyx Inc (NASDAQ:ARDX) has risen 41.40% since March 7, 2016 and is uptrending. It has outperformed by 33.81% the S&P500.
The move comes after 5 months positive chart setup for the $661.48M company. It was reported on Oct, 10 by Barchart.com. We have $22.15 PT which if reached, will make NASDAQ:ARDX worth $363.81M more.
Analysts await Ardelyx Inc (NASDAQ:ARDX) to report earnings on November, 10. They expect $-0.70 EPS, 0.00% or $0.00 from last year’s $-0.7 per share. After $-0.83 actual EPS reported by Ardelyx Inc for the previous quarter, Wall Street now forecasts -15.66% EPS growth.
Ardelyx Inc (NASDAQ:ARDX) Ratings Coverage
Out of 5 analysts covering Ardelyx Inc (NASDAQ:ARDX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ardelyx Inc has been the topic of 7 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The rating was maintained by Wedbush on Thursday, September 3 with “Buy”. The firm earned “Buy” rating on Tuesday, September 22 by BTIG Research. The stock of Ardelyx Inc (NASDAQ:ARDX) earned “Buy” rating by Citigroup on Wednesday, August 10. The firm has “Buy” rating given on Friday, December 18 by BTIG Research. Ladenburg Thalmann initiated Ardelyx Inc (NASDAQ:ARDX) rating on Thursday, March 31. Ladenburg Thalmann has “Buy” rating and $21 price target. The company was maintained on Wednesday, March 9 by JMP Securities.
According to Zacks Investment Research, “Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company’s lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California.”
More notable recent Ardelyx Inc (NASDAQ:ARDX) news were published by: Marketwatch.com which released: “Ardelyx Inc. NASDAQ: ARDX” on June 19, 2014, also Quotes.Wsj.com with their article: “Ardelyx Inc. ARDX (US: Nasdaq)” published on May 22, 2013, Prnewswire.com published: “Ardelyx Receives Notice of Allowance of Composition of Matter Patent Covering …” on August 01, 2016. More interesting news about Ardelyx Inc (NASDAQ:ARDX) were released by: Prnewswire.com and their article: “Ardelyx Reports Progress of Development Programs” published on June 22, 2016 as well as Prnewswire.com‘s news article titled: “Ardelyx to Raise $110 Million in a Private Placement” with publication date: July 15, 2016.
ARDX Company Profile
Ardelyx, Inc., incorporated on October 18, 2007, is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Firm operates through research, development and commercialization of biopharmaceutical products segment. The Firm has developed drug discovery and design platform to discover and design drug candidates. Utilizing its platform, the Company has discovered and designed its lead product candidate, tenapanor. The Company’s development programs also include RDX009 Program, RDX013 Program and RDX011 Program. The Firm also owns NaP2b inhibitor compounds. NaP2b is an intestinal transporter of dietary phosphorus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.